BioStock: Chordate sums up H1 and projects sales growth

It has been an eventful first half of the year for Chordate Medical, including a list change to Nasdaq First North and an ongoing market introduction in Saudi Arabia and the UK. In addition, the company has fully recruited the migraine study and completed the first phase of the process to obtain market approval in the United States. BioStock had a chat with CEO Anders Weilandt about these events and his expectations for the autumn.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/chordate-sums-up-h1-and-projects-sales-growth/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se